Blog

PARIS - Friday, October 5th 2012 [ME NewsWire]

BUSINESS WIRE / ME Newswire-- Organized as part of the CARTES trade show, the SESAMES Awards reward the best technological innovations in terms of smart cards, digital security, identification, secure transactions and contactless since 1995.

The projects submitted are presented to 38 jury members, international experts recognized in their field, who choose the finalists and the winners of the SESAMES Awards, in total impartiality and confidentiality of entries, thus highlighting the most dynamic and most ingenious companies.

The SESAMES Awards reward the best projects in 10 categories. For the first time this year, the SESAMES Discovery will give an award to the best innovation presented by a start-up company. The SESAMES Awards’ finalists will be presented at CARTES in the SESAMES Area, hall 4. The Winners will be announced during the SESAMES Awards Ceremony, on November 5th, 2012 (upon invitation).

Discover the 36 finalists:

Hardware

    Advanced Card Systems Ltd. with "ACR1222U-J4 Li-ion Web-To Reader"
    Cinterion with "Firmware & Patient data Security for medical device"
    NXP SEMICONDUCTORS with "Next Generation NFC Radio Controller"

Software

    Intrinsic-ID with "Secure Cloud application"
    Morpho with "Network Triggered Multi-IMSI"
    Rosberg System AS with "Extreme Secure Smart Device"

Identification / ID Cards / Health

    NXP SEMICONDUCTORS with "OpenWays Mobile Key DUAL© with Pure NFC™"
    Sunward Telecom Limited with "13.56MHz RF-SIM"
    Vision-Box with "vb i-dispenser"

IT Security

    DS3 with "DS3 Multi-purpose Authentication Server"
    Entersekt with "Interactive Transaction Athentication"
    Morpho with "EMV Pro Digit"

Transportation

    Infineon Technologies AG with "Security Controller for Transport Applications"
    KENTKART EGE ELEKTRONIK A.S. with "Onboard Public Transportation Tablet"
    Turkcell with "Turkcell Wallett Road Toll Payment Service"

Banking / Retail / Loyalty

    AIRTAG with "AIRFID"
    Toro Development Ltd. with "Akami suite"
    Turkcell with "Turckcell Home Delivery Service with Smart Magnets"

Trusted Internet / Authentication

    NXP Semiconductors Austria GmbH with "Mobile POS for eTicket and stored value reload"
    Tatra banka with "Card&Reader"
    Vlatacom with "VLAD-1"

Mobility

    Intrinsic-ID with "Secure Cloud application"
    Oberthur Technologies with "Multi-brand NFC payment wallet"
    Printechnologics GmbH with "Touchcode"

e-Transactions

    Elavon Merchant Services with "Elavon MobileMerchant"
    Fiteq with "EMV MultiTeq-TagTeq"
    Giesecke & Devrient with "Portigo"
    Synqera with "Simplate"

Manufacturing & tests

    Gemalto with "PrintPixel"
    Gemalto with "Sealys Edge Sealer"
    MGI Digital Graphic Tehnology with "JETcard 3D"
    OBERTHUR TECHNOLOGIES with "PaperSIM card"

Discovery

    Bridget with "B-Smart Packaging"
    Coded Imagery with "Personalisation of ID with Biometric Watermarks"
    Kuapay LLC with "Kuapay"
    RCDEVS SARL with "OpenOTP/TiQR Authentication Server"

To follow the trade show in real time:

    follow us on Twitter "@_cartes" and on our blog www.blogcartes.com
    visit our website: www.cartes.com

About CARTES 2012: The CARTES 2012 show, taking place from 6 to 8 November at the Parc des Expositions in Paris-Nord Villepinte, is the world's leading event in smart technologies for security, payment, identification and mobility. With 143 countries represented, 450 exhibitors and 140 conferences with international experts, CARTES 2012 is an essential trade show for all the players in this highly dynamic market. This year, for its 27th edition, CARTES 2012 is putting the spotlight on India.

Contacts

Press Contact

Actifin

Marie-Caroline Cardi

+331 56 88 11 13

 

Jennifer Jullia

+331 56 88 11 19

cartes@actifin.fr

Cette initiative d'avant-garde réduit l'impact environnemental des évènements organisés, sans frais pour les clients

SINGAPOUR - Dimanche 7 Octobre 2012 [ME NewsWire]

(BUSINESS WIRE)--Hilton Worldwide a lancé aujourd'hui un programme de compensation carbone pour les évènements et les réunions se déroulant dans certains de ses établissements en Asie du Sud-Est. Sans frais supplémentaires pour les clients, Hilton Worldwide mesurera les émissions de carbone de toutes les manifestations dans 11 de ses établissements en Malaisie, à Singapour et en Thaïlande, et achètera des crédits carbone pour compenser leur impact sur l'environnement. Les crédits carbone seront utilisés pour financer des projets dans le domaine des énergies renouvelables à Bornéo et au Cambodge.

« Le développement durable est une priorité pour Hilton Worldwide ; il est au cœur de nos activités. Pour nous, il ne s'agit pas juste de dire que nous nous engageons dans ce domaine, mais il s'agit de prendre des mesures », a déclaré William Costley, vice-président chargé des opérations en Asie du Sud-Est chez Hilton Worldwide. « Ce programme propose aux organisations et aux personnes une option durable pour leurs conférences, réunions ou évènements sociaux. En compensant les émissions de carbone sans frais supplémentaires pour nos clients, nous pouvons, ensemble, rendre à l'environnement ce qu'il nous donne et en faire profiter d'importants projets mis en œuvre dans la région dans le domaine des énergies renouvelables. »

Hilton Worldwide est le premier et le seul grand groupe hôtelier multimarques à faire des actions de durabilité et des mesures correctives sa marque de fabrique dans chacun de ses 3 900 hôtels dans le monde.

Ce programme porte sur les manifestations organisées à partir du 1er octobre 2012. Il couvre tous les évènements comme les réunions, les conférences, les mariages et autres réceptions organisés dans les espaces de réception des hôtels participant à l'opération. Hilton Worldwide utilisera son instrument LightStay™ Meeting Impact Calculator pour suivre et mesurer les émissions de carbone de chaque évènement. Cet instrument de calcul prend en compte de nombreux facteurs, notamment la consommation d'eau et d'électricité, les aliments consommés et les chambres réservées. LightStay™ est le système exclusif de Hilton Worldwide destiné à analyser, consigner et améliorer les performances de durabilité dans chacun de ses établissements dans le monde. Il offre aux hôtels des outils et des ressources leur permettant d'améliorer leurs performances et de partager leurs bonnes pratiques.

Selon LightStay™, Hilton Worldwide a atteint son objectif quinquennal de réduction de 20% de ses déchets ; le groupe est en bonne voie de diminuer sa consommation énergétique et ses émissions de CO2de 20% ainsi que sa consommation d'eau de 10% d'ici 2013.

En collaboration avec Climate Friendly, un fournisseur de solutions de compensation carbone, Hilton Worldwide a identifié deux premiers bénéficiaires pour son programme de compensation carbone en Asie du Sud-Est. Il s'agit du Projet de régénération de la forêt tropicale à Bornéo et du Projet Foyers de cuisson au Cambodge.

« Les organisations sont de plus en plus soucieuses de l'impact de leur activité sur l'environnement », a déclaré William Costley. « Le programme de compensation carbone mis en œuvre par Hilton Worldwide en Asie du Sud-Est permet aux établissements de mesurer l'impact environnemental de leurs évènements et de compenser cet impact de manière pertinente. »

Voici les hôtels participant à la phase de lancement du programme :

    Conrad Centennial Singapore
    Hilton Singapore
    Hilton Kuala Lumpur
    DoubleTree by Hilton Kuala Lumpur
    Hilton Petaling Jaya
    Hilton Kuching
    Millennium Hilton Bangkok
    Conrad Bangkok
    Hilton Phuket Arcadia Resort & Spa
    Hilton Pattaya
    Hilton Hua Hin Resort & Spa

Pour un complément d'information :

Découvrez Hilton MICE en Asie du Sud-Est

Découvrez le Programme de compensation carbone de Hilton Worldwide en Asie du Sud-Est

À propos du Projet de régénération de la forêt tropicale à Bornéo

Le Projet de régénération de la forêt tropicale à Bornéo (Borneo Rainforest Rehabilitation Project) vise à restaurer les forêts tropicales de Sabah, en Malaisie, et à développer l'espace vital pour les espèces sauvages comme les orangs-outangs, les ours malais, les gibbons, les éléphants pygmées et le rhinocéros de Sumatra, en voie de disparition. En outre, la régénération de la forêt contribuera à abaisser les niveaux de gaz à effet de serre dans l'atmosphère.

À propos du Projet Foyers de cuisson au Cambodge

Le Projet Foyers de cuisson au Cambodge (Cambodian Cookstove Project) est axé sur la production et la diffusion massive d'un foyer de cuisson à haute efficacité énergétique, le New Lao Stove. Près de 90% des Cambodgiens dépendent au quotidien du bois de chauffage et du charbon de bois pour cuisiner leurs repas, ce qui contribue à l'épuisement des ressources forestières. Le New Lao Stove permet d'économiser 22% de bois et de charbon de bois par rapport aux réchauds traditionnels. L'utilisation généralisée du New Lao Stove doit contribuer à réduire les émissions de gaz à effet de serre et à préserver les forêts du Cambodge.

À propos de LightStay™

LightStay™ est un système exclusif développé pour calculer et analyser les performances de durabilité. LightStay™ mesure plusieurs paramètres utilitaires et opérationnels tels que l'énergie, l'eau, le carbone, l'aménagement, l'utilisation de produits en papier, les déchets, le stockage de produits chimiques, la qualité de l'air et les transports (liste non exhaustive). De plus, LightStay™ fournit des outils de réseautage social qui permettent aux établissements de communiquer et de partager des informations ; il est doté d'un « calculateur d'impact des réunions » qui évalue l'impact sur la durabilité des réunions ou conférences qui ont lieu dans un établissement. Hilton Worldwide est la première entreprise hôtelière multimarques à faire de la mesure de la durabilité sa marque de fabrique ; elle vient d'obtenir les certifications ISO 9001 et 14001 pour sa gestion de la qualité et de l'environnement – parmi les plus importantes certifications accordées à des bâtiments commerciaux en termes de volume. Rien qu'en 2010, l'entreprise a économisé plus de 74 millions de dollars de coûts en réduisant de 6,6% sa consommation énergétique, de 7,8% ses émissions de carbone, de 19% sa production de déchets, et de 3,8% sa consommation d'eau.www.HiltonWorldwide.com/corporate-responsibility/

À propos de Hilton Worldwide

Hilton Worldwide est l'un des plus importants groupes hôteliers au monde, proposant toute la gamme d'hébergements, depuis des centres de villégiature et des hôtels offrant les services complets les plus luxueux en passant par des appartements dédiés aux longs séjours et des hôtels de moyenne gamme. Depuis 93 ans, Hilton Worldwide propose aux voyageurs d'affaires et de loisirs ce qu'il y a de mieux en termes d'hébergement, de service, de confort et de rapport qualité/prix. La société reste fidèle à sa tradition : offrir à ses clients une expérience de séjour exceptionnelle dans toutes ses marques mondiales. Ses marques, qui comprennent Waldorf Astoria Hotels & Resorts, Conrad Hotels & Resorts, Hilton Hotels & Resorts, DoubleTree by Hilton, Embassy Suites Hotels, Hilton Garden Inn, Hampton Hotels, Homewood Suites by Hilton, Home2 Suites by Hilton et Hilton Grand Vacations, regroupent plus de 3 900 hôtels et propriétés à temps partagé, avec en tout 640 000 chambres proposées dans 91 pays. La société gère également le programme de fidélisation de renommée mondiale Hilton HHonors®. Pour de plus amples renseignements, veuillez consulter www.hiltonworldwide.com et vous connecter à Hilton Worldwide surwww.facebook.com/hiltonworldwide, www.twitter.com/hiltonworldwide, www.youtube.com/hiltonworldwide, www.flickr.com/hiltonworldwide et www.linkedin.com/company/hilton-worldwide.

À propos de Climate Friendly

Climate Friendly est le premier prestataire australien fournissant des certificats de compensation carbone et d'énergie renouvelable. Fondé en 2003, sa clientèle est mondiale. Son offre complète de services de grande qualité font de Climate Friendly le prestataire de référence de nombreuses organisations dans le monde. www.climatefriendly.com

Photos/Galerie multimédia disponibles: http://www.businesswire.com/cgi-bin/mmg.cgi?eid=50428916&lang=fr

Le texte du communiqué issu d’une traduction ne doit d’aucune manière être considéré comme officiel. La seule version du communiqué qui fasse foi est celle du communiqué dans sa langue d’origine. La traduction devra toujours être confrontée au texte source, qui fera jurisprudence.

Contacts

Audrey Wong

Hilton Worldwide Asie-Pacifique

+65 6833 9763

audrey.wong@hilton.com

 

HOUSTON - Thursday, October 4th 2012 [ME NewsWire]

(BUSINESS WIRE)-- KBR (NYSE: KBR) announced today that it was awarded a License and Process Design Package contract by Jiutai Energy Group (Jiutai) for its Methanol to Olefins (MTO) Recovery Project in Dalu New Area, Zhungeer Banner, Ordos, Inner Mongolia, China.

KBR’s MTO technology will be used in the recovery process for Jiutai’s 600 KTA ethylene and propylene unit. The recovery process will take 1,800 KTA methanol to the MTO Reactor and convert it. The effluent from the MTO Reactor will then enter KBR MTO Recovery to separate 600 KTA polymer grade ethylene product and propylene product.

“We are pleased with the increased response from clients for KBR MTO Recovery Technology,” said John Derbyshire, president, KBR Technology. “This project builds upon KBR’s more than 60-year history of olefins production and recovery. We are honored that Jiutai has selected KBR MTO Recovery Technology and look forward to delivering superior performance on this milestone project. Asia is one of the fastest growing regions with a very high demand for consumer products made from ethylene and propylene. This process will be key in the production of propylene and ethylene, both very important commodity products in the future.”

Jiutai was established in 2002 and has been listed on the main board of the Stock Exchange of Singapore (named “China Energy“) since 2006. Jiutai is a National High-technology enterprise, and mainly produce 1,300 KTA methanol and 1,100 KTA diethyl ether (DME) with the production facilities in Linyi, Shangdong; Ordos, Inner Mongolia; Guangzhou, Guangdong; Zhangjiang, Jiangsu; Beijing. Jiutai developed its own DME technology and is the largest DME producer in the world at present.

KBR is a global engineering, construction and services company supporting the energy, hydrocarbon, government services, minerals, civil infrastructure, power, industrial, and commercial markets. For more information, visit www.kbr.com.

Contacts

KBR

Zac Nagle, 713-753-3625

Vice President,

Investor Relations and Communications

Investors@kbr.com

 

Marianne Gooch

Director, Corporate Communications

Media Relations Hotline: 713-753-3800

Mediarelations@kbr.com

pls like  9jabook on facebook   

9jabook.com is an Idea a supposition that men not only make books. books also make men.Give your Friends the gift of Knowledge invite them to 9jabook.com A knowledge content social network with a strong focus on educating/mentoring our youth ..if interested pls inbox knowledge@systemini.net for our programs ..the book of 9ja ! facebook is great but face your books and 9jabook rent-an-effico Internet consulting for your business simple straight & affordable see email bottom for more announcements http://www.awoof.mebrowse and shop ! b.uyers & s.ellers no payments required a blog a day keeps the dreams from fading away ! we are giving out 2,500 naira recharge credit weekly to our top bloggers ! it could be you this week ! Ladies ! email your photo to be displayed on our facebooks on 9jabook to 9jababe@systemini.net need a job: Become a 9jabook webkudi mumzycard reseller and Agent and web payment specialist. email cv to mumzycardsreseller@systemini.netand create account on webkudi.com  skype=biodunb facebook=www.facebook.com/9jabook twitter=www.twitter.com/pimpmy9jabook lagos..PH..Abuja..Kaduna.. Owerri..Edo.. AkwaIbom..Ibadan..Enugu politics..music..dating..tech..food..properties..health..netchurch find friends..jobs rent-an-effico.. soccer scores Tweet9ja Twitter Tracker bookthis: to err is human to earn might cost an arm but when it comes to learning stop erring and start earning  Give your Friends the gift of Knowledge invite them to 9jabook.com !      fine boys and girlz dey 9jabook click foto find dem !

Headlines:

Weekend Photo: Na Dem start Am 

OUR NEW BBPIN IS 28CF2E4B

Netchurch: Placebo by howard pittman 2nd 3rd heavens an expose !

On August 3, 1979, Howard Pittman, a Baptist minister for 35 years, died while on the operating table during surgery and had a near death e…

Started by you in Netchurch

Toothless Lion as Tinubu Loses Own Local Govt to Obanikoro's Son we are "bored ill on" ACN- locals say Huhuonline.com can disclose that the Lagos State Election Tribunal, sitting in Lagos, has declared Ibrahim Babajide Obanikoro, son of one-t… Started by you in politics punch pmnews reporters 234next	0	49 seconds ago
UK: Nigerian rapist proposes to victim, threatens with juju by Agency Reporter advertisement A teenager has told a court how a Nigerian man accused of threatening girls with 'black magic' to try and… Started by you in Black Planet Nigeria from America	0	5 minutes ago
143 UNIBEN students arrested for forgery Management of the University of Benin, on Wednesday said it had handed over to the police 143 of its students for certificate forgery. The… Started by you in EFCC Nigeria Crime Reports	0	6 minutes ago
How Deputy Governor of Taraba State Impeached the Taraba State House of Assembly, Friday afternoon, finally sacked the state Deputy Governor, Sanni Abubakar Danladi, over gross miscondu… Started by you in politics punch pmnews reporters 234next	0	55 minutes ago
Jonathan Appoints New Service Chiefs The change was expected, seniority was a benchmark for the change and Goodluck Jonathan did not disappoint, when he elevated Vice Admiral O… Started by you in politics punch pmnews reporters 234next	0	59 minutes ago
Nigeria floods kill dozens, wash hippos and crocodiles into homes (CNN) -- Ravaging floods killed dozens in Nigeria and displaced tens of thousands of residents as crocodiles, hippos and other water animal… Started by you in naijalife	0	1 hour ago
Nigeria: Government poised to launch $15m ICT sector venture fund Nigeria’s ICT sector is set for a boom after the government announced plans to launch a $15-million venture fund, CP Africa reports. The fu… Started by you in Weboga:Technology & Science techstartup nigeria	0	1 hour ago
Professor Obama Vs Politician Romney by Ozodi Thomas Osuji, PhD A few minutes ago the first Presidential debate between Mr. Barack Obama and Mr. Mitt Romney ended.   Here is my impression of what I saw.M… Started by you in News of the world cnn allafrica nigeria	0	1 hour ago
TWITTER: The real Twuth ! It's Not A Mainstream Technology Twitter is a great product, and millions of people have become addicted to using it for many hours per day (including me). Investors have a… Started by you in Weboga:Technology & Science techstartup nigeria	0	1 hour ago
Not the same sesame street: Once upon a time there was Big Bird and Mr. Snuffleupagus. Look, I get it. Big Bird is a sentimental hero. Everyone who's over 40 remembers watching Big Bird when they were kids. Big Bird and Mr. Sn… Started by you in Education

9jabook.com is an Idea a supposition that men not only make books. books also make men.

Do you know that you can publicise your upcoming event(s) to over 50,000 people on our 9jax.net network ? O Yes !
It's fast and real easy and at NO CHARGE ! click on the "Events" link on our homepage !

if am lying then am dying if am learning then am earning ! join the 9jabook project ! Offer back by popular demand ! http://bit.ly/own9jabook

OUR NEW BBPIN IS 28CF2E4B    skype=biodunb facebook=www.facebook.com/9jabook twitter=www.twitter.com/pimpmy9jabook

gbagam & getsense ! http://www.gbagam.com/you probbaly had sense but it is time to gbagam and get sense !

0 y

HOUSTON - Thursday, October 4th 2012 [ME NewsWire]

(BUSINESS WIRE)-- KBR (NYSE: KBR) announced today that it was awarded a contract by Statoil Tanzania AS (Statoil) to perform pre-front end engineering and design (pre-FEED) studies for a prospective liquefied natural gas (LNG) facility in Tanzania, East Africa.

The pre-FEED study is designed to help Statoil further assess the viability of developing an LNG facility to export natural gas from this East African region. The project is expected to be completed during 2013.

“We are excited to be selected by Statoil for this important project,” said Mitch Dauzat, president, Gas Monetization. “KBR looks forward to working together with Statoil to define their LNG concept for Tanzania.”

KBR has been working with Statoil for more than 30 years and has an outstanding record for successful project execution, predominantly for Statoil’s Gas Processing plants.

KBR is a global engineering, construction and services company supporting the energy, hydrocarbon, government services, minerals, civil infrastructure, power, industrial, and commercial markets. For more information, visit www.kbr.com.

Contacts

KBR

Zac Nagle, 713-753-3625

Vice President, Investor Relations and Communications

Investors@kbr.com

 

Marianne Gooch, 713-753-3800

Director, Corporate Communications

Mediarelations@kbr.com

BUSINESS WIRE / ME NewsWire - BERLIN - Wednesday, October 3rd 2012

 Phase III Trials of MK-3102 Underway

Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced Phase IIb data for MK-3102, the company’s investigational once-weekly DPP-4 inhibitor in development for the treatment of type 2 diabetes. MK-3102 significantly lowered blood sugar in this 12-week study compared with placebo, with an incidence of symptomatic hypoglycemia that was similar to placebo, in patients with type 2 diabetes. These data were presented today at the 48th Annual Meeting of the European Association for the Study of Diabetes (EASD) in Berlin.

“If approved, MK-3102 would provide a novel, once-weekly treatment option to help reduce blood sugar levels in patients with type 2 diabetes,” said lead study author Ira Gantz, M.D., Clinical Research, Metabolism, Merck Research Laboratories.

Study Design

The findings reported today are from a multicenter, randomized, double-blind, placebo-controlled dose-ranging study designed to evaluate five doses of MK-3102 (0.25, 1, 3, 10 and 25 mg) in patients with type 2 diabetes who had inadequate glycemic control on diet and exercise.

A total of 685 patients with a mean baseline HbA1c of approximately 8 percent were randomized: 571 patients received MK-3102 at one of the five once-weekly doses (0.25 mg, n=113; 1 mg, n=115; 3 mg, n=114; 10 mg, n=115; 25 mg, n=114) and 114 patients received placebo for 12 weeks. The primary endpoint was change in HbA1c from baseline at 12 weeks compared to placebo across doses. The secondary endpoints were 2-hour post-meal glucose and fasting plasma glucose.

Study Results

MK-3102 significantly reduced HbA1c compared to placebo (p<0.001) from a mean baseline of approximately 8 percent across all doses. In the full study population at 12 weeks, the placebo-adjusted reduction from baseline in HbA1c was 0.71 percent with MK-3102 25 mg; 0.67 percent with 10 mg; 0.49 percent with 3 mg; 0.50 percent with 1 mg; and 0.28 percent with 0.25 mg.

A statistically significant (p<0.001) trend was observed across doses studied for the secondary endpoints of 2-hour post-meal glucose (PMG) and fasting blood glucose (FPG). For 2-hour PMG placebo-adjusted reductions from baseline at week 12 were: MK-3102 25 mg=2.5 mmol/L; 10 mg=2.3 mmol/L; 3 mg=1.9 mmol/L; 1 mg=1.9 mmol/L; 0.25 mg=1.0 mmol/L. For FPG, placebo-adjusted reductions from baseline at week 12 were MK-3102 25 mg=1.2 mmol/L; 10 mg=0.7 mmol/L; 3 mg=0.8 mmol/L; 1 mg=1.1 mmol/L; 0.25 mg=0.1 mmol/L.

In the study, MK-3102 was generally well tolerated with a safety profile that was generally similar to placebo.

Diabetes is a chronic, progressive disease that affects 366 million people globally, including nearly 26 million people in the U.S., however, based on National Health and Nutrition Examination Survey (NHANES) data from 1999-2006, more than 40 percent of patients are not at the American Diabetes Association (ADA) goal of less than 7.0 percent for HbA1c.

“Since the discovery of the DPP-4 inhibitor class, Merck has been actively committed to advancing the science of how to treat type 2 diabetes. We are encouraged by these Phase IIb results in patients with type 2 diabetes, and we are initiating Phase III studies to move MK-3102 forward in the development process,” said Nancy Thornberry, Senior Vice President and Franchise Head, Diabetes and Endocrinology, Merck Research Laboratories.

About Merck

Today’s Merck is a global healthcare leader working to help the world be well. Merck is known as MSD outside the United States and Canada. Through our prescription medicines, vaccines, biologic therapies, and consumer care and animal health products, we work with customers and operate in more than 140 countries to deliver innovative health solutions. We also demonstrate our commitment to increasing access to healthcare through far-reaching policies, programs and partnerships. For more information, visit www.merck.com and connect with us on Twitter, Facebook and YouTube.

Forward-Looking Statement

This news release includes “forward-looking statements” within the meaning of the safe harbor provisions of the United States Private Securities Litigation Reform Act of 1995. Such statements may include, but are not limited to, statements about the benefits of the merger between Merck and Schering-Plough, including future financial and operating results, the combined company’s plans, objectives, expectations and intentions and other statements that are not historical facts. Such statements are based upon the current beliefs and expectations of Merck’s management and are subject to significant risks and uncertainties. Actual results may differ from those set forth in the forward-looking statements.

The following factors, among others, could cause actual results to differ from those set forth in the forward-looking statements: the possibility that all of the expected synergies from the merger of Merck and Schering-Plough will not be realized, or will not be realized within the expected time period; the impact of pharmaceutical industry regulation and health care legislation in the United States and internationally; Merck’s ability to accurately predict future market conditions; dependence on the effectiveness of Merck’s patents and other protections for innovative products; and the exposure to litigation and/or regulatory actions.

Merck undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events or otherwise. Additional factors that could cause results to differ materially from those described in the forward-looking statements can be found in Merck’s 2011 Annual Report on Form 10-K and the company’s other filings with the Securities and Exchange Commission (SEC) available at the SEC’s Internet site (www.sec.gov).

Contacts

Merck

Media

Pam Eisele, +1 908-423-5042

 

Kim Hamilton, +1 908-423-6831

 

Investor

Carol Ferguson, +1 908-423-4465

 

Justin Holko, +1-908-423-5088

 

The Spirit itself beareth witness with our spirit, that we are the children of God: And if children, then heirs; heirs of God, and joint-heirs with Christ if so be that we suffer with him, that we may be also glorified together (Romans 8.16-17).

If you’re born again, you have an inheritance and it was bequeathed to you by the Monarch of the universe— the one who said “The silver is mine, and the gold is mine, saith the LORD of hosts” (Haggai 2:8). All the wealth in this world actually belong to Him: the money, precious stones, minerals, oil and everything that men believe they own all belong to the Lord and you’re His heir. You’re the heir of the sovereign-mega-rich God. He is the fountain of riches. His wealth is limitless, inestimable and unquantifiable. That makes you richer than those on the Forbes’ list! Hallelujah!

Your ‘Papa’s’ wealth isn’t subject to the market forces of this world; it isn’t subject to the oil prices or the stability of the world’s currencies. That’s why it’s an insult to God for His kids to be broke or live beggarly lives. What you must learn to do is tap into this limitless wealth by faith through your confessions. Begin to voice out your faith; declare everyday that you’re rich and blessed beyond measure.

Meditate on this reality and let the consciousness of your inheritance in God fill your spirit. Get rid of the poverty-talk. Your heavenly Father has bequeathed His enormous wealth to you, and unlike the wills made by men on behalf of their beneficiaries, He isn’t dead—He’s alive and will see to it that nothing deprives you of your inheritance.  Praise the Lord. have blessed day.

BOUDRY, Switzerland - Wednesday, October 3rd 2012 [ME NewsWire]

BUSINESS WIRE / ME Newswire-- Celgene International Sàrl, a subsidiary of Celgene Corporation (NASDAQ: CELG) today announced results of its phase III, randomized, international study (CA033) of ABRAXANE® (paclitaxel protein-bound particles for injectable suspension) (albumin-bound) in chemotherapy-naïve patients with metastatic melanoma. In the study, the primary endpoint was met with patients receiving ABRAXANE demonstrating a statistically significant improvement in progression-free survival compared to patients receiving dacarbazine (DTIC) chemotherapy.

The safety profile of ABRAXANE observed in the CA033 study is consistent with other ABRAXANE pivotal clinical trials. Data from this study will be presented at the Society for Melanoma Research (SMR) Congress 2012 in Los Angeles in November. Future regulatory and clinical strategies are being reviewed in light of these results.

The CA033 study is a Celgene-sponsored, open-label, controlled, randomized study comparing ABRAXANE to standard chemotherapy, DTIC, in patients with metastatic melanoma. DTIC is the only chemotherapy approved since 1975 by the U.S. Food and Drug Administration for metastatic melanoma. In the study, 529 chemotherapy-naïve patients were randomized to receive either ABRAXANE (150mg/m2 weekly for 3 out of 4 weeks) or DTIC (1000 mg/m2 every three weeks). The primary study endpoint was independently-assessed progression free survival. Secondary endpoints included overall survival, overall response rate and disease control, safety and tolerability.

These results are from an investigational study. ABRAXANE® is not approved for the treatment of metastatic melanoma.

ABRAXANE® for Injectable Suspension (paclitaxel protein-bound particles for injectable suspension) is indicated for the treatment of breast cancer after failure of combination chemotherapy for metastatic disease or relapse within 6 months of adjuvant chemotherapy. Prior therapy should have included an anthracycline unless clinically contraindicated.

Important Safety Information

WARNING - NEUTROPENIA

    ABRAXANE therapy should not be administered to patients with metastatic breast cancer who have baseline neutrophil counts of less than 1,500 cells/mm3. In order to monitor the occurrence of bone marrow suppression, primarily neutropenia, which may be severe and result in infection, it is recommended that frequent peripheral blood cell counts be performed on all patients receiving ABRAXANE.
    Note: An albumin form of paclitaxel may substantially affect a drug’s functional properties relative to those of drug in solution. DO NOT SUBSTITUTE FOR OR WITH OTHER PACLITAXEL FORMULATIONS.

CONTRAINDICATIONS

Neutrophil Counts

    ABRAXANE should not be used in patients who have baseline neutrophils counts of < 1,500 cells/mm3

Hypersensitivity

    Patients who experience a severe hypersensitivity reaction to ABRAXANE should not be rechallenged with the drug

WARNINGS AND PRECAUTIONS

Hematologic Effects

    Bone marrow suppression (primarily neutropenia) is dose dependent and a dose limiting toxicity
    In order to monitor the occurrence of myelotoxicity, perform frequent peripheral blood cell counts
    Retreat with subsequent cycles of ABRAXANE after neutrophils recover to a level >1,500 cells/mm3 and platelets recover to >100,000 cells/mm3
    In the case of severe neutropenia (<500 cells/mm3 for 7 days or more), during a course of ABRAXANE therapy, dose reduce for subsequent courses of therapy

Nervous System

    Sensory neuropathy occurs frequently with ABRAXANE
    The occurrence of grade 1 or 2 sensory neuropathy does not generally require dose modification
    If grade 3 sensory neuropathy develops, treatment should be withheld until resolution to grade 1 or 2 followed by a dose reduction for all subsequent courses of ABRAXANE

Hypersensitivity

    Severe and sometimes fatal hypersensitivity reactions, including anaphylactic reactions, have been reported
    Patients who experience severe hypersensitivity reaction to ABRAXANE should not be re-challenged with this drug

Hepatic Impairment

    Because the exposure and toxicity of paclitaxel can be increased with hepatic impairment, administration of ABRAXANE in patients with hepatic impairment should be performed with caution
    The starting dose should be reduced for patients with moderate and severe hepatic impairment

Albumin (Human)

    ABRAXANE contains albumin (human), a derivative of human blood

Use in Pregnancy: Pregnancy Category D

    ABRAXANE can cause fetal harm when administered to a pregnant woman
    There are no adequate and well-controlled studies in pregnant women receiving ABRAXANE
    If this drug is used during pregnancy, or if the patient becomes pregnant while receiving this drug, the patient should be apprised of the potential hazard to the fetus
    Women of childbearing potential should be advised to avoid becoming pregnant while receiving ABRAXANE

Use in Men:

    Men should be advised to not father a child while receiving ABRAXANE

ADVERSE REACTIONS - Randomized Metastatic Breast Cancer Study

    Severe cardiovascular events possibly related to single-agent ABRAXANE occurred in approximately 3% of patients. These events included cardiac ischemia/infarction, chest pain, cardiac arrest, supraventricular tachycardia, edema, thrombosis, pulmonary thromboembolism, pulmonary emboli, and hypertension
    Cases of cerebrovascular attacks (strokes) and transient ischemic attacks have been reported
    In the randomized metastatic breast cancer study, the most common adverse events (≥20%) were alopecia (90%), neutropenia (all cases 80%; severe 9%), sensory neuropathy (any symptoms 71%; severe 10%), abnormal ECG (all patients 60%, patients with normal baseline 35%), asthenia (any 47%; severe 8%), myalgia/arthralgia (any 44%; severe 8%), AST (SGOT) elevations (any 39%), alkaline phosphatase elevations (any 36%), anemia (all cases 33%; severe 1%), nausea (any 30%; severe 3%), diarrhea (any 27%; severe <1%) and infections (24%). Other adverse events of note include vomiting (any 18%; severe 4%), and mucositis (any 7%; severe <1%). 3% (7 of 229) of patients discontinued the use of ABRAXANE due to sensory neuropathy
    Other adverse events have included ocular/visual disturbances (any 13%; severe 1%), renal dysfunction (any 11%; severe 1%), fluid retention (any 10%; severe 0%), hepatic dysfunction (elevations in bilirubin 7%), hypersensitivity reactions (any 4%; severe 0%), cardiovascular reactions (severe 3%), thrombocytopenia (any 2%; severe <1%), and injection site reactions (<1%). Dehydration and pyrexia were also reported

Post-Marketing Experience with ABRAXANE and other Paclitaxel Formulations

    Severe hypersensitivity reactions have also been reported with ABRAXANE
    During postmarketing surveillance, reports of congestive heart failure and left ventricular dysfunction were observed, primarily among individuals with underlying cardiac history or prior exposure to cardiotoxic drugs like anthracyclines
    There have been reports of extravasation of ABRAXANE. Given the possibility of extravasation, it is advisable to monitor closely the ABRAXANE infusion site for possible infiltration during drug administration

DRUG INTERACTIONS:

    No drug interaction studies have been conducted with ABRAXANE
    Caution should be exercised when administering ABRAXANE concomitantly with medicines known to inhibit or induce either CYP2C8 or CYP3A4

USE IN SPECIFIC POPULATIONS

Nursing Mothers:

    It is not known whether paclitaxel is excreted in human milk
    Because many drugs are excreted in human milk and because of the potential for serious adverse reactions in nursing infants, a decision should be made to discontinue nursing or to discontinue the drug, taking into account the importance of the drug to the mother

Pediatric:

    The safety and efficacy of ABRAXANE in pediatric patients have not been evaluated

Geriatric:

    No toxicities occurred notably more frequently among patients ≥ 65 years of age who received ABRAXANE

Renal Impairment:

    The use of ABRAXANE has not been studied in patients with renal impairment
    Patients were excluded for baseline serum bilirubin >1.5 mg/dL or baseline serum creatinine > 2 mg/dL

DOSAGE AND ADMINISTRATION

    Dose adjustment is recommended for patients with moderate and severe hepatic impairment and patients who experience severe neutropenia or severe sensory neuropathy during treatment with ABRAXANE

Please see full Prescribing Information, including Boxed WARNING, CONTRAINDICATIONS, WARNINGS AND PRECAUTIONS, and ADVERSE REACTIONS.

About Melanoma

Melanoma is a form of skin cancer characterized by the uncontrolled growth of pigment-producing cells (melanocytes) located in the skin. When melanoma is diagnosed early, it is generally a curable disease. However, when it spreads to other parts of the body, it is the deadliest and most aggressive form of skin cancer. A person with metastatic melanoma typically has on average a short life expectancy that is measured in months. According to the World Health Organization, approximately 132,000 new cases of melanoma are diagnosed each year globally. The incidence of melanoma has increased ten-fold over the past 50 years, and has steadily increased since the 1970s. The American Cancer Society estimates there will be more than 76,000 new cases of melanoma and nearly 9,200 melanoma deaths this year in the United States.

About Celgene International Sàrl

Celgene International Sàrl, located in Boudry, in the Canton of Neuchâtel, Switzerland, is a wholly owned subsidiary and international headquarters of Celgene Corporation. Celgene Corporation, headquartered in Summit, New Jersey, is an integrated global pharmaceutical company engaged primarily in the discovery, development and commercialization of innovative therapies for the treatment of cancer and inflammatory diseases through gene and protein regulation. For more information, please visit the Company's website at www.celgene.com.

Forward-Looking Statements

This press release contains forward-looking statements, which are generally statements that are not historical facts. Forward-looking statements can be identified by the words "expects," "anticipates," "believes," "intends," "estimates," "plans," "will," “outlook” and similar expressions. Forward-looking statements are based on management’s current plans, estimates, assumptions and projections, and speak only as of the date they are made. We undertake no obligation to update any forward-looking statement in light of new information or future events, except as otherwise required by law. Forward-looking statements involve inherent risks and uncertainties, most of which are difficult to predict and are generally beyond our control. Actual results or outcomes may differ materially from those implied by the forward-looking statements as a result of the impact of a number of factors, many of which are discussed in more detail in our Annual Report on Form 10-K and our other reports filed with the Securities and Exchange Commission.

Contacts

For Celgene International Sàrl

Investors:

+41 32 729 8303 ir@celgene.com

 

Media:

+41 32 729 8304 media@celgene.com

 

'Global Pink Ribbons' initiative unites GE staff around the world to continue raising disease awareness

BUSINESS WIRE / ME NewsWire - CHALFONT ST. GILES, England - Tuesday, October 2nd 2012

GE Healthcare today announced its second ‘GE Global Pink Ribbons’ campaign will run in over 40 global locations during October 2012.

Building on the success of last year’s events, several thousand GE employees will come together to form ‘Human Ribbons’ and visually demonstrate the global fight against the disease during Breast Cancer Awareness Month. New countries taking part this year include Egypt, Venezuela and Ukraine. To follow the activities, see how the importance of awareness and early detection of breast cancer is being raised visit the GE Healthcare Newsroom and Breast Cancer Mosaic site - which is a dedicated site created to share stories from breast cancer survivors, family members and physicians to increase awareness around breast cancer and to inspire those who are going through a difficult time.

“We envision a day when cancer is no longer a deadly disease. Building on GE’s cancer commitment, we aim to bring the most promising cancer ideas to market, develop technologies that improve accuracy of diagnosis and enable more effective treatment decisions, and empower doctors and patients with better information,” said John Dineen, President and CEO of GE Healthcare.

Dineen continued, “Emphasis on awareness building and early diagnosis will significantly enhance the effectiveness of treatment and reduce healthcare costs. The Global Ribbons campaign is important as it spreads the powerful message that early detection can save lives.”

Awareness of the importance of early detection of breast cancer continues to be an important issue in both developed and developing countries; as worldwide breast cancer remains the most common invasive cancer in women. In 2008, breast cancer caused almost 460, 000 deaths worldwide, almost 14% of cancer deaths in women. 1 Lack of access to appropriate facilities, up-to-date imaging technologies or trained medical professionals mean that even today two-thirds of all women around the world must forgo regular breast screenings. In addition to raising awareness during Breast Cancer Awareness Month, GE Healthcare is committed to reaching many of these women through a series of in-country partnerships with governments, NGOs and local health partners that can help mobilize efforts on the ground in regions.

In addition to these “GE Global Pink Ribbons” events, GE Healthcare raises awareness around the battle against cancer through multiple online and social media channels.

    The #GetFit competition encouraged individuals and teams to post their healthy lifestyle choices on Twitter, Weibo or Facebook using the #GetFit hashtag; reinforcing the importance of a positive healthy lifestyle in cancer prevention. #GetFit cancer country ambassadors were showcased on Pinterest.
    GE recently launched the HealthyShare Facebook App. This new tool is a channel for people to share health goals, track progress against goals and use friends as sources of inspiration and motivation toward better health.
    In an effort to educate about the importance of asking questions for those diagnosed with cancer, and inform about how individualized cancer diagnostics and treatments can help drive positive outcomes, Is My Cancer Different? has been established as a resource.
    Later this month through the power of music, the company will launch an initiative based on Spotify, to support breast cancer patients.

GE Healthcare has been a recognized pioneer in the battle against cancer for over fifty years and last year announced a healthymagination commitment to help 10 million patients around the world by 2020. The investment commitment, $1bn over the next five years, is dedicated to R&D and delivery of better care for patients through expansion of its world-class technologies as well as advanced cancer diagnostic and molecular imaging capabilities.

Images available at http://www.flickr.com/photos/gehealthcare/sets/72157627809160108/

1 “World Cancer Report”. International Agency for Research on Cancer, 2008

About GE Healthcare

GE Healthcare provides transformational medical technologies and services that are shaping a new age of patient care. Our broad expertise in medical imaging and information technologies, medical diagnostics, patient monitoring systems, drug discovery, biopharmaceutical manufacturing technologies, performance improvement and performance solutions services help our customers to deliver better care to more people around the world at a lower cost. In addition, we partner with healthcare leaders, striving to leverage the global policy change necessary to implement a successful shift to sustainable healthcare systems.

Our “healthymagination” vision for the future invites the world to join us on our journey as we continuously develop innovations focused on reducing costs, increasing access and improving quality around the world. Headquartered in the United Kingdom, GE Healthcare is a unit of General Electric Company (NYSE: GE). Worldwide, GE Healthcare employees are committed to serving healthcare professionals and their patients in more than 100 countries. For more information about GE Healthcare, visit our website at www.gehealthcare.com

For our latest news, please visit http://newsroom.gehealthcare.com

Contacts

GE Healthcare

Allison J. Cohen

Global Corporate Public Relations

and Communications Manager

+972 547 299 742

allison.cohen@ge.com   

Dubai, United Arab Emirates - Monday, October 1st 2012 [ME NewsWire]

LinkedIn, the world's largest professional network with more than 175 million members worldwide, today announced the opening of its first office in the Middle East and North Africa,[1] where a new team will support a growing membership and client base.

Located in Dubai’s Internet City, the office will serve as regional headquarters to over five million members in the Middle East and North Africa, one million of which are based in the UAE.

Farhan Syed, Director, Global Sales Strategy, LinkedIn commented, “We are very excited to be opening an office here in Dubai - a city recognized by the world as a crossroads for global business exchange. Members are already networking in over 2,000 LinkedIn Groups in the region, exchanging strategic business insights and exploring opportunities together. Having a strong local presence will help serve our members better here, ultimately making them more productive and successful”.

Speaking at the local launch of LinkedIn, Fadi Salem, Director, Governance and Innovation Program, Dubai School of Government, "Our research in the Arab Social Media Report series shows that the MENA region has witnessed exponential growth in social media usage, with usage trends shifting from primarily fulfilling social needs back in 2010 to political and societal usage in 2011.

“In 2012 strong growth continues, coupled with maturity and yet another shift in usage trends, where a critical mass of users now heavily relying on such social media platforms to develop new business and entrepreneurial initiatives. We are witnessing increased opportunities for employment, start-ups and social entrepreneurship leading to economic empowerment of a large group of youth in the region."

To address its growing customer base, LinkedIn has also appointed Ali Matar as Head of Hiring Solutions, MENA. Matar will be responsible for growing LinkedIn’s Hiring Solutions business which enable employers to find and recruit the best active and passive talent.

LinkedIn also represents a valuable demographic for marketers with affluent and influential members. LinkedIn Marketing Solutions will continue to be mostly sold through its partnership with Clique Media to local clients.

This latest expansion follows the opening of LinkedIn’s Spanish office in March, and brings the number of LinkedIn offices in EMEA to nine, including Paris, Milan, Stockholm, London, Munich,  Dublin, Amsterdam, Madrid and now Dubai.

BUSINESS WIRE - ME NewsWire LONDON - Monday, October 1st 2012

The insurance, reinsurance, Takaful and cooperative markets within the Middle East and North Africa (MENA) continue to offer opportunity for growth, although the global slowdown of financial markets and political instability in the region threaten to dampen prospects for some companies, according to a new report from A.M. Best Co.

Whilst the MENA insurance markets have experienced double-digit premium growth in recent years, the pace of growth has slowed in 2011 and 2012, with most markets expected to achieve increases in total gross premiums written (GPW) of less than 5% this year. Movements in GPW have been more pronounced in countries affected by the Arab Spring where growth has either declined or stagnated in 2011, with difficult trading conditions in 2012.

Mahesh Mistry, associate director, analytics, said, “Competition in the MENA markets remains fierce, as a number of companies seek topline growth, and increasing market share is a priority. This has been exacerbated in recent years by the increasing number of new entrants into the market.”

The report, “Political Unrest Overshadows MENA’s Strong Insurance Demand”, found leading insurers have attempted to restructure their operations and achieve a profile more commensurate to their international peers. A number of companies have adopted a more prudent investment policy—de-risking from volatile asset classes such as equities and real estate, with a shift toward a more liquid investment portfolio—which should generate a steady income stream to supplement underwriting activities. In addition, regulators’ actions to introduce stricter guidelines should expedite requirements for a more prudent allocation of investments.

Yvette Essen, report author and director of industry research, Europe and emerging markets, said, “The MENA insurance markets tend to be immature, with very low penetration rates compared to more developed international markets. There is greater demand for insurance as the awareness of the benefits of insurance grows and regulators encourage its take-up with the introduction of compulsory lines of business.” She adds, “Obligatory medical schemes are considered to present the greatest opportunities in the region, although they remain fiercely competitive and need to be controlled to produce profitable growth.”

To access a complimentary copy of this report, please visit www.ambest.com/press/100101menaspecialreport.pdf.

Founded in 1899, A.M. Best Company is the world's oldest and most authoritative insurance rating and information source. For more information, visit www.ambest.com.

Copyright © 2012 by A.M. Best Company, Inc. ALL RIGHTS RESERVED.

Contacts

A.M. Best Co.

Mahesh Mistry, +(44) 20 7397 0325

Associate Director, Analytics

mahesh.mistry@ambest.com

Rachelle Morrow, +(1) 908 4392200, ext. 5378

Senior Manager, Public Relations

rachelle.morrow@ambest.com

Yvette Essen, +(44) 20 7397 0322

Director, Industry Research

Europe& Emerging Markets

yvette.essen@ambest.com

Jim Peavy, +(1) 908 439 2200, ext. 5644

Assistant Vice President, Public Relations

james.peavy@ambest.com